citalopram has been researched along with Symptom Cluster in 17 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to determine the efficacy of non-hormonal therapy with citalopram vs fluoxetine for treating vasomotor syndrome (VMS) and urogenital syndrome of menopause (GSM) in Mexican women." | 9.51 | Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial. ( Álvarez-Pérez, MA; Bajonero-Domínguez, A; Cruz-Luna, M; Garmendia-Gallardo, C; González-Quiroz, JL; Hernández-Castañón, MY; Hernández-Hernández, VY; Loranca-Moreno, P; Ocampo-Godínez, JM; Rios-Espinosa, A; Sánchez-Tinoco, PM; Vergara Lope-Núñez, JA, 2022) |
| " We report here a case of Drug Reaction with Eosinophilia and Systemic Symptoms apparently precipitated by the associated use of lamotrigine and cyclobenzaprine." | 7.78 | Erythema multiforme vs. DRESS syndrome associated with the combined use of lamotrigine and cyclobenzaprine: a case report. ( Bicknell, LT; Sanches, M; Schatte, DJ, 2012) |
| "This study aimed to determine the efficacy of non-hormonal therapy with citalopram vs fluoxetine for treating vasomotor syndrome (VMS) and urogenital syndrome of menopause (GSM) in Mexican women." | 5.51 | Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial. ( Álvarez-Pérez, MA; Bajonero-Domínguez, A; Cruz-Luna, M; Garmendia-Gallardo, C; González-Quiroz, JL; Hernández-Castañón, MY; Hernández-Hernández, VY; Loranca-Moreno, P; Ocampo-Godínez, JM; Rios-Espinosa, A; Sánchez-Tinoco, PM; Vergara Lope-Núñez, JA, 2022) |
| "The syndrome has been extensively described in children, but less information is available about adult patienis." | 5.31 | Wolf-Hirschhorn (4p-)syndrome in a near adult with major depression; successful treatment with citalopram. ( Moog, U; Tuinier, S; Verhoeven, WM; Wagemans, AM, 2002) |
| " We report here a case of Drug Reaction with Eosinophilia and Systemic Symptoms apparently precipitated by the associated use of lamotrigine and cyclobenzaprine." | 3.78 | Erythema multiforme vs. DRESS syndrome associated with the combined use of lamotrigine and cyclobenzaprine: a case report. ( Bicknell, LT; Sanches, M; Schatte, DJ, 2012) |
| "Fibromyalgia is a clinically well-defined chronic condition with a biopsychosocial aetiology." | 2.52 | Selective serotonin reuptake inhibitors for fibromyalgia syndrome. ( Cantrell, SE; Häuser, W; Nishishinya, MB; Urrútia, G; Walitt, B, 2015) |
| "The syndrome has been extensively described in children, but less information is available about adult patienis." | 1.31 | Wolf-Hirschhorn (4p-)syndrome in a near adult with major depression; successful treatment with citalopram. ( Moog, U; Tuinier, S; Verhoeven, WM; Wagemans, AM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Rios-Espinosa, A | 1 |
| Cruz-Luna, M | 1 |
| Garmendia-Gallardo, C | 1 |
| Hernández-Castañón, MY | 1 |
| Hernández-Hernández, VY | 1 |
| Sánchez-Tinoco, PM | 1 |
| Bajonero-Domínguez, A | 1 |
| Vergara Lope-Núñez, JA | 1 |
| Álvarez-Pérez, MA | 1 |
| González-Quiroz, JL | 1 |
| Loranca-Moreno, P | 1 |
| Ocampo-Godínez, JM | 1 |
| Eren, OE | 1 |
| Schöberl, F | 1 |
| Schankin, CJ | 1 |
| Straube, A | 1 |
| Na, PJ | 1 |
| Adhikari, S | 1 |
| Szuhany, KL | 1 |
| Chen, AZ | 1 |
| Suzuki, RR | 1 |
| Malgaroli, M | 1 |
| Robinaugh, DJ | 1 |
| Bui, E | 1 |
| Mauro, C | 1 |
| Skritskaya, NA | 1 |
| Lebowitz, BD | 1 |
| Zisook, S | 1 |
| Reynolds, CF | 1 |
| Shear, MK | 1 |
| Simon, NM | 1 |
| Gkini, MA | 1 |
| Taylor, RE | 1 |
| Bewley, AP | 1 |
| Bergman, Y | 1 |
| Barak, Y | 1 |
| Bicknell, LT | 1 |
| Sanches, M | 1 |
| Schatte, DJ | 1 |
| Walitt, B | 1 |
| Urrútia, G | 1 |
| Nishishinya, MB | 1 |
| Cantrell, SE | 1 |
| Häuser, W | 1 |
| Masmoudi, J | 1 |
| Feki, I | 1 |
| Trigui, D | 1 |
| Baati, I | 1 |
| Jaoua, A | 1 |
| Chekroud, AM | 1 |
| Gueorguieva, R | 1 |
| Krumholz, HM | 1 |
| Trivedi, MH | 1 |
| Krystal, JH | 1 |
| McCarthy, G | 1 |
| Auyeung, SF | 1 |
| Long, Q | 1 |
| Royster, EB | 1 |
| Murthy, S | 1 |
| McNutt, MD | 1 |
| Lawson, D | 1 |
| Miller, A | 1 |
| Manatunga, A | 1 |
| Musselman, DL | 1 |
| Padala, PR | 1 |
| Padala, KP | 1 |
| Monga, V | 1 |
| Ramirez, DA | 1 |
| Sullivan, DH | 1 |
| Verhoeven, WM | 1 |
| Moog, U | 1 |
| Wagemans, AM | 1 |
| Tuinier, S | 1 |
| Mahgoub, NA | 1 |
| Hossain, A | 1 |
| Kozian, R | 1 |
| Kessler, H | 1 |
| Kraft, S | 1 |
| Fischer, P | 1 |
| Tietz, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause[NCT05346445] | 91 participants (Actual) | Interventional | 2021-01-20 | Completed | |||
| Optimizing Treatment for Complicated Grief (Healing Emotions After Loss:HEAL)[NCT01179568] | Phase 2 | 395 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The 19-item self-report instrument assesses symptoms of complicated grief. Responses on individual items are added up to a total score, which can range from 0 to 76 with higher scores indicating more intense symptoms. This scale has been utilized previously in treatment studies of CG. Additional times points include weeks 4, 8, 12, 16, 20 and 40. For the pre-specified analyses we compared change in the ICG total score from baseline (calculated as baseline score minus week 12 score) for CIT vs PLA at week 12 (aim 1), based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 12
| Intervention | score change from baseline to wk12 (Mean) |
|---|---|
| Citalopram (CIT) | 18 |
| Placebo (PLA; Sugar Pill) | 16 |
The 19-item self-report instrument assesses symptoms of complicated grief. Responses on individual items are added up to a total score, which can range from 0 to 76 with higher scores indicating more intense symptoms. This scale has been utilized previously in treatment studies of CG. Additional times points include weeks 4, 8, 12, 16, 20 and 40. For the pre-specified analyses we compared change in the ICG total score from baseline (calculated as baseline score minus week 20 score) for CIT with CGT vs PLA with CGT (aim 2), and for CIT with CGT vs CIT (aim 3) based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 20
| Intervention | score change from baseline to wk20 (Mean) |
|---|---|
| Citalopram (CIT) | 20 |
| Complicated Grief Treatment With Citalopram (CGT With CIT) | 25 |
| Complicated Grief Treatment With Placebo (CGT With PLA) | 26 |
The WSAS is a modification of a scale introduced by Hafner and Marks (1976), consisting of 0-8 point ratings of the extent to which symptoms interfere with five areas of daily functioning: work, home management, private leisure, social leisure, and family relationships. It is a well-validated, widely used self-report measure. Additional time points include weeks 4, 8, 12, 16, and 40. A total score calculated as a sum of all items (possible range 0-40) was used in the analyses with higher scores indicating more impairment. For the pre-specified analyses we compared change in the WSAS total score from baseline (calculated as baseline score minus week 12 score) for CIT vs PLA at week 12 (aim 1), based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 12
| Intervention | score change from baseline to wk12 (Mean) |
|---|---|
| Citalopram (CIT) | 10 |
| Placebo (PLA; Sugar Pill) | 8 |
The WSAS is a modification of a scale introduced by Hafner and Marks (1976), consisting of 0-8 point ratings of the extent to which symptoms interfere with five areas of daily functioning: work, home management, private leisure, social leisure, and family relationships. It is a well-validated, widely used self-report measure. Additional time points include weeks 4, 8, 12, 16, and 40. A total score calculated as a sum of all items (possible range 0-40) was used in the analyses with higher scores indicating more impairment. For the pre-specified analyses we compared change in the WSAS total score from baseline (calculated as baseline score minus week 20 score) for CIT with CGT vs PLA with CGT (aim 2), and for CIT with CGT vs CIT (aim 3) based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 20
| Intervention | score change from baseline to wk20 (Mean) |
|---|---|
| Citalopram (CIT) | 10 |
| Complicated Grief Treatment With Citalopram (CGT With CIT) | 14 |
| Complicated Grief Treatment With Placebo (CGT With PLA) | 16 |
Brief rating scale frequently used in clinical trials. For this study, version modified for complicated grief was be used. Response is defined as a score of 1(very much improved) or 2 (much improved) on the scale. The rating was done by an Independent Evaluator. (NCT01179568)
Timeframe: Weeks 12 and 20
| Intervention | percentage of responders (Number) |
|---|---|
| Citalopram (CIT) | 46 |
| Placebo (PLA; Sugar Pill) | 38 |
| Complicated Grief Treatment With Citalopram (CGT With CIT) | 84 |
| Complicated Grief Treatment With Placebo (CGT With PLA) | 83 |
2 reviews available for citalopram and Symptom Cluster
| Article | Year |
|---|---|
Selective serotonin reuptake inhibitors for fibromyalgia syndrome.
Topics: Amitriptyline; Citalopram; Fibromyalgia; Fluoxetine; Humans; Melatonin; Musculoskeletal Pain; Paroxe | 2015 |
[Neuropsychiatric symptoms in Sotos syndrome. Case report and review of the literature].
Topics: Adult; Antipsychotic Agents; Brain; Carbamazepine; Chromosome Deletion; Citalopram; Compulsive Behav | 2008 |
2 trials available for citalopram and Symptom Cluster
| Article | Year |
|---|---|
Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial.
Topics: Citalopram; Female; Fluoxetine; Humans; Menopause; Postmenopause; Prospective Studies; Syndrome | 2022 |
Posttraumatic Distress Symptoms and Their Response to Treatment in Adults With Prolonged Grief Disorder.
Topics: Adult; Aged; Behavioral Symptoms; Citalopram; Combined Modality Therapy; Female; Grief; Humans; Long | 2021 |
13 other studies available for citalopram and Symptom Cluster
| Article | Year |
|---|---|
Visual snow syndrome after start of citalopram-novel insights into underlying pathophysiology.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression, Postpartum; Female; Humans; Select | 2021 |
Olfactory reference syndrome (ORS) successfully treated with a selective serotonin reuptake inhibitor.
Topics: Citalopram; Diagnostic and Statistical Manual of Mental Disorders; Humans; Hypochondriasis; Male; Od | 2017 |
Escitalopram for antipsychotic nonresponsive visual hallucinosis: eight patients suffering from Charles Bonnet syndrome.
Topics: Aged, 80 and over; Citalopram; Eye Diseases; Female; Hallucinations; Humans; Male; Psychotic Disorde | 2013 |
Erythema multiforme vs. DRESS syndrome associated with the combined use of lamotrigine and cyclobenzaprine: a case report.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Antimanic Agents; Citalopram; Diagnosis, Differenti | 2012 |
[Complex visual hallucinations secondary to corneal transplant: The Charles Bonnet syndrome].
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Corneal Transplantation; Hallucinations; | 2015 |
Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents; Bupropion; Citalopram; Cluster Analysis; Dep | 2017 |
Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy.
Topics: Behavioral Symptoms; Citalopram; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Doubl | 2009 |
Reversal of SSRI-associated apathy syndrome by discontinuation of therapy.
Topics: Aged; Antidepressive Agents; Apathy; Citalopram; Depressive Disorder; Fluoxetine; Humans; Male; Midd | 2012 |
Wolf-Hirschhorn (4p-)syndrome in a near adult with major depression; successful treatment with citalopram.
Topics: Abnormalities, Multiple; Adolescent; Antidepressive Agents, Second-Generation; Chromosome Deletion; | 2002 |
Cotard's syndrome and electroconvulsive therapy.
Topics: Benzodiazepines; Citalopram; Combined Modality Therapy; Delusions; Depressive Disorder, Major; Elect | 2004 |
[Brief case report. Duloxetine in Cotard syndrome].
Topics: Affective Disorders, Psychotic; Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; | 2005 |
Serotonin syndrome in the elderly after antidepressive monotherapy.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Benzamid | 1995 |
[Stage CDC C3 HIV infection; V.a. acute serotoninergic syndrome].
Topics: Adult; AIDS-Related Opportunistic Infections; Citalopram; Diagnosis, Differential; Drug Therapy, Com | 1997 |